Literature DB >> 32696289

Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles.

Kemal Ozgur1, Murat Berkkanoglu1, Hasan Bulut1, Levent Donmez2, Kevin Coetzee3.   

Abstract

PURPOSE: To compare the effectivity of flexible-start medroxyprogesterone acetate (MPA) co-treatment ovarian stimulations (OS) with flexible-start gonadotropin-releasing hormone antagonist (GnRH-ant) co-treatment OS, in blastocyst freeze-all IVF cycles.
METHOD: This matched cohort study was performed at a single IVF center. Study cycles were extracted from freeze-all IVF cycles performed between February 2015 and June 2018 with cycles grouped according to the co-treatment protocol (MPA and GnRH-ant groups) used. MPA cycles were matched 1:1 using antral follicle count, female age, infertility duration, and female body mass index, with GnRH-ant cycles, resulting in 825 matched cycles. MPA or CET co-treatment was started when leading follicles reached 11-12 mm.
RESULTS: Duration of OS was significantly longer, and total FSH dose was significantly higher in the MPA group. Numbers of mature oocytes retrieved were similar; however, the mature oocyte retrieval rate (83.8 vs. 97.1%; p < 0.001), number of blastocysts, blastocyst rate (36.4 vs. 41.4%; p < 0.001) and > 2 viable blastocyst rate were all significantly lower in the MPA group. The live birth (LB) per transfer rates (51.6 vs. 55.7%; p = 0.155) were similar; however, the LB rate per treatment was significantly lower (40.9 vs. 45.8%; p = 0.05). A linear regression included the OS co-treatment protocol (GnRH-ant; 1.4 (1.07-1.81); p = 0.013) in the final model to predict having > 2 viable blastocysts.
CONCLUSION: Flexible-start MPA co-treatment OS was as effective in freeze-all IVF cycles as GnRH-ant co-treatment, with similar LB per transfer rates; however, increased cycle cancellation and reduced blastocyst numbers reduced LB per treatment rates significantly.

Entities:  

Keywords:  Co-treatment; Flexible start; Freeze-all IVF; Medroxyprogesterone acetate; Ovarian stimulation

Mesh:

Substances:

Year:  2020        PMID: 32696289      PMCID: PMC7492309          DOI: 10.1007/s10815-020-01894-4

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  31 in total

1.  Agonist depot versus OCP programming of frozen embryo transfer: a retrospective analysis of freeze-all cycles.

Authors:  Kemal Ozgur; Murat Berkkanoglu; Hasan Bulut; Peter Humaidan; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2015-12-23       Impact factor: 3.412

2.  The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting.

Authors: 
Journal:  Hum Reprod       Date:  2011-04-18       Impact factor: 6.918

Review 3.  New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF.

Authors:  Nathalie Massin
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

4.  Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?

Authors:  Panagiotis Drakopoulos; Christophe Blockeel; Dominic Stoop; Michel Camus; Michel de Vos; Herman Tournaye; Nikolaos P Polyzos
Journal:  Hum Reprod       Date:  2016-01-02       Impact factor: 6.918

5.  Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population.

Authors:  Kemal Ozgur; Hasan Bulut; Murat Berkkanoglu; Levent Donmez; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2019-02-21       Impact factor: 3.412

6.  Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.

Authors:  Xiuxian Zhu; Hongjuan Ye; Yonglun Fu
Journal:  Fertil Steril       Date:  2016-11-16       Impact factor: 7.329

7.  Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology.

Authors:  Sule Yildiz; Engin Turkgeldi; Berk Angun; Alper Eraslan; Bulent Urman; Baris Ata
Journal:  Fertil Steril       Date:  2019-07-29       Impact factor: 7.329

8.  Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders.

Authors:  Qiuju Chen; Yun Wang; Lihua Sun; Shaozhen Zhang; Weiran Chai; Qingqing Hong; Hui Long; Li Wang; Qifeng Lyu; Yanping Kuang
Journal:  Reprod Biol Endocrinol       Date:  2017-09-05       Impact factor: 5.211

9.  Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles.

Authors:  Lihua Sun; Jing Ye; Yun Wang; Qiuju Chen; Renfei Cai; Yonglun Fu; Hui Tian; Qifeng Lyu; Xuefeng Lu; Yanping Kuang
Journal:  Sci Rep       Date:  2018-09-14       Impact factor: 4.379

10.  Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.

Authors:  Yun Wang; Qiuju Chen; NingLing Wang; Hong Chen; Qifeng Lyu; Yanping Kuang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.